Equitable Holdings Inc. Makes New $6.95 Million Investment in Abbott Laboratories $ABT

Equitable Holdings Inc. purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 76,578 shares of the healthcare product maker’s stock, valued at approximately $6,949,000.

A number of other hedge funds have also recently modified their holdings of ABT. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories in the fourth quarter worth approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.5%

NYSE:ABT opened at $110.52 on Thursday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The stock’s fifty day moving average is $103.83 and its two-hundred day moving average is $100.09. The stock has a market capitalization of $191.24 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 2.02 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the firm posted $1.26 earnings per share. The company’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 81.55%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ABT shares. Citigroup lifted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. UBS Group lowered their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, July 28th. Robert W. Baird began coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective on the stock. TD Cowen upped their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Finally, Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.